OPKO Health Inc
NASDAQ:OPK
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.8655
1.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OPKO Health Inc
OPKO Health Inc
Net Income
OPKO Health Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OPKO Health Inc
NASDAQ:OPK
|
Net Income
-$133.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
OPKO Health Inc
Glance View
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 5,767 full-time employees. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. The company also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.
See Also
What is OPKO Health Inc's Net Income?
Net Income
-133.7m
USD
Based on the financial report for Sep 30, 2024, OPKO Health Inc's Net Income amounts to -133.7m USD.
What is OPKO Health Inc's Net Income growth rate?
Net Income CAGR 10Y
0%
Over the last year, the Net Income growth was 36%.
You don't have any saved screeners yet
